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Alzheimer's diseaseare characterized by a relentlessly progressive loss of the functional and struc-
tural integrity of the central nervous system. In many cases, these diseases arise sporadically and the causes
are unknown. The abnormal aggregation of protein within the cytoplasm or the nucleus of brain cells
represents a unifying pathological feature of these diseases. There is increasing evidence for nuclear
dysfunction in neurodegenerative diseases. How this relates to protein aggregation in the context of “cause
and effect” remains to be determined in most cases. Co-ordinated nuclear function is predicated on the
activity of distinct nuclear subdomains, or nuclear bodies, each responsible for a speciﬁc function. If nuclear
dysfunction represents an important etiopathological feature in neurodegenerative disease, then this should
be reﬂected by functional and/or morphological alterations in this nuclear compartmentalization. For most
neurodegenerative diseases, evidence for nuclear dysfunction, with attendant consequences for nuclear
architecture, is only beginning to emerge. In this review, I will discuss neurodegenerative diseases in the
context of nuclear dysfunction and, more speciﬁcally, alterations in nuclear bodies. Although research in this
ﬁeld is in its infancy, identifying alterations in the nucleus in neurodegenerative disease has potentially
profound implications for elucidating the pathogenesis of these disorders.
© 2008 Elsevier B.V. All rights reserved.1. IntroductionNeurodegenerative diseases are relentlessly progressive disorders
of the central nervous system characterized by cognitive, motor, and/
or behavioural dysfunction. This clinical heterogeneity is in large part
attributable to pathological variability and to the characteristic
topographic pattern of CNS involvement displayed by each particular
disease entity, the latter being determined by selective vulnerability of
populations of brain cells to the disease process. Abnormal protein
aggregation represents a unifying biochemical and histomorphologi-
cal hallmark of neurodegenerative disease [1]. The classiﬁcation of
neurodegenerative diseases is increasingly becoming based on the
identity of the protein which accumulates (Table 1). In most cases,
these protein aggregates form microscopically-visible cellular depos-
its called “inclusion bodies”. In the majority of cases, these inclusion
bodies are located in the cytoplasmic compartment. Accordingly,
studies of disease pathogenesis have historically focused on aspects of
aberrant protein biochemistry occurring in this part of the cell. The
discovery that protein aggregation within the nuclear compartment
represented a pathological hallmark of Huntington's disease [2,3],
inculcated the nuclear compartment into the cast of cellular players
known to contribute to neurodegenerative pathogenesis. Aberrant
nuclear structure, function, or both, are emerging as important patho-l rights reserved.genetic mediators in a growing number of neurodegenerative diseases
[4]. For example, aberrant nucleocytoplasmic transport of transcrip-
tion factors resulting in their abnormal cytoplasmic accumulation is
increasingly recognized in several neurodegenerative disorders [5].
Moreover, in some diseases with primary nuclear involvement, for
example the RNA-mediated disease myotonic dystrophy, the histo-
morphological changes in the nervous system are reminiscent of those
described for more common sporadic neurodegenerative conditions,
such as Alzheimer's disease (AD) [6]. This capacity for nuclear dys-
function to induce Alzheimer-like changes in the brain makes it
tempting to invoke a nuclear contribution to the pathophysiology of
AD and other common sporadic neurodegenerative conditions.
The concept of structural and functional compartmentaliza-
tion within the nucleus is well-established [7]. Thus, individual
nuclear bodies have been ascribed particular functional roles. These
nuclear bodies include those most relevant to the discussion below
such as Cajal bodies (or coiled bodies; CBs) and gemini of coiled bodies
or “gems”, both involved in small nuclear ribonucleoprotein (snRNP)
metabolism and synthesis of the spliceosome [7], PML bodies involved
in a variety of intranuclear functions [8], and splicing speckles or
interchromatin granule clusters which represent sites of pre-mRNA
splicing [9]. There is a growing list of additional nuclear bodies in-
cluding cleavage bodies, matrix-associated deacetylase bodies, HAP
bodies, nucleolar paraspeckles and clastosomes. The structure and
function of nuclear bodies are reviewed in greater detail in the other
reviews provided in this special issue. An important corollary of this
nuclear compartmentalization is that disease-associated nuclear
Table 1
Protein-based classiﬁcation of neurodegenerative disease
Tauopathies
Alzheimer's disease
Amyotrophic lateral sclerosis/Parkinson-dementia complex
Argyrophilic grain disease
Corticobasal degeneration
Dementia pugilistica
Diffuse neuroﬁbrillary tangles with calciﬁcation
Down's syndrome
Frontotemporal dementia/parkinsonism linked to chromosome 17
Gerstmann–Straussler–Scheinker disease
Guadeloupian parkinsonism
Myotonic dystrophy
Niemann-Pick disease type C
Pick's disease
Postencephalitic parkinsonism
Progressive subcortical gliosis
Progressive supranuclear palsy
Subacute sclerosing panencephalitis
Tangle only dementia
Synucleinopathies
Parkinson's disease
Dementia with Lewy bodies
Multiple system atrophy
Neurodegeneration with brain iron accumulation
Pure autonomic failure
Meige's syndrome
Prion Proteinipathies
Creutzfeld–Jakob disease (familial, sporadic, and transmitted)
Fatal insomnia (familial and sporadic)
Gerstmann–Straussler–Scheinker disease
Kuru
Polyglutaminopathies
Huntington's disease
Dentatorubropallidoluysian atrophy
Spinal and bulbar muscular atrophy (Kennedy's disease)
Spinocerebellar ataxia 1, 2, 3, 6, 7, and 17
TDP-43 proteinopathies
Frontotemporal lobar degeneration with ubiquitin-only inclusions
Amyotrophic lateral sclerosis
RNA-mediated diseases
Fragile X-associated tremor ataxia syndrome
Myotonic dystrophy
Spinocerebellar ataxias 8, 10, 12
Huntington's disease-like type 2
Others
Neuronal intermediate ﬁlament inclusion body disease
Neuronal intranuclear inclusion disease
Neuroferritinopathy
TDP-43-negative FTLD-U
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the nuclear bodies whose functions are disrupted by the disease
process. Thus, in acute promyelocytic leukemia (APL), the pathogenic t
(15;17) chromosomal translocation results in a chimeric PML-RARα
fusion protein with attendant disruption of intranuclear PML bodies
[10,11]. Interestingly, the clinical response to treatment with ATRA
correlates with relocalization of PML to PML bodies [11,12]. The
concept of a similar involvement of nuclear bodies in neurodegen-
erative disease is beginning to emerge.
The focus of this review will be on neurodegenerative disease
afﬂicting the central nervosus system. Thus, diseases primarily af-
fecting muscle for which alterations in nuclear bodies have been
described, (for example fascioscapulohumeral muscular dystrophy
[13]), will not be discussed in great detail. The ﬁrst section concerns
difﬁculties in interpreting the cause-and-effect status of nuclear
morphological alterations in the context of disease pathogenesis.
Spinal muscular atrophy will then be discussed as an archetypalexample of a neurodegenerative disease in which nuclear body
alterations have been directly implicated in disease pathogenesis. For
adult neurodegenerative diseases, the majority of studies concerning
nuclear bodies thus far have focused on how they interact with, and
are affected by, microscopically-visible, proteinaceous, pathological
nuclear inclusion bodies. Therefore, I will discuss alterations in
nuclear bodies in the “nuclear inclusion diseases”, concentrating on
the polyglutamine (polyQ) repeat disorders. Finally, the discussion
will focus on nuclear dysfunction and known or potential nuclear
body alterations in the more common, “canonical” adult neurode-
generative diseases including Alzheimer's disease, Parkinson's dis-
ease, frontotemporal dementia, and amyotrophic lateral sclerosis.
2. Generalized nuclear changes in neurodegenerative disease
In some neurodegenerative diseases, there is evidence that re-
organization of nuclear compartments may reﬂect a primary intra-
nuclear pathogenetic event. However other nuclear alterations may
represent generalized consequences of the neurodegenerative process
with, nonetheless, important pathogenetic and therapeutic implica-
tions. For example, a variety of environmental stress conditions, some
of which may occur along the neurodegenerative cascade, have been
demonstrated to result in marked nuclear body alterations. Examples
include amino acid starvation, high temperature, osmotic changes,
exposure to heavy metals, and cellular senescence [11]. There is
growing evidence for generalized involvement of nuclear foci contain-
ing elements of the DNA-damage/repair mechanism in several neuro-
degenerative diseases [14]. This may be associated with a number of
nuclear morphological alterations. Germane to this discussion are the
observations of Valero and co-workers in mitral cells of the Purkinje
cell degeneration (pcd) mutant mouse [15]. These mice harbour a
recessive mutation in the nna1 gene which encodes a nuclear protein
involved in neuronal differentiation and regeneration [16]. They
undergo selective degeneration of speciﬁc neuronal populations,
including mitral cells in the olfactory bulb. In the latter, the authors
described the formation of abnormally enlarged DNA-damage/repair
foci containing the phosphorylated formof the histone variant H2AX, a
sensor of DNA damage, as well as phosphorylated ataxia telangiectasia
mutated (ATM) protein, a protein kinase that responds to DNAdamage.
This was associated with evidence of transcriptional downregulation
with a reduction in the number and intensity of acetylated histone H4
and RNA polymerase II foci, the formation of large perinucleolar
masses of trimethylated histone, an increase in the size and number of
heterochromatin masses, and segregation of nucleoli. Most impor-
tantly in the context of this reviewwas the ﬁnding that nuclear bodies,
speciﬁcally coiled bodies (CBs) and splicing speckles, were disrupted.
Both coilin and survival motor neuron protein (SMN) were re-dis-
tributed from the typical CBs seen in control cells to perinucleolar caps.
Splicing factors of pre-mRNAs were re-organized into large, irregular
nuclear speckles. Because these changeswere observed in cells lacking
morphological evidence of degeneration, they were considered a very
early manifestation, or “predegenerative” in nature. The transcrip-
tional and nuclear body alterations were proposed to reﬂect a
dysfunction of gene expression and pre-mRNA processing, respec-
tively, as a consequence of the accumulation of DNA-damage foci.
Because there is increasing evidence that DNA damage may be a
general feature of neurodegenerative disease, the secondary altera-
tions in nuclear bodies as described in this study, must be dis-
tinguished from nuclear morphological alterations more proximate to
the causative molecular lesion.
3. Spinal muscular atrophy
Spinal muscular atrophy (SMA) is a common autosomal recessive
neurodegenerative disease characterized by progressive muscle
weakness and wasting. It is the leading cause of inherited infant
2197J. Woulfe / Biochimica et Biophysica Acta 1783 (2008) 2195–2206mortality [17]. Pathologically, it is characterized by the loss of spinal
cord anterior horn alpha motor neurons with consequent denervation
of skeletal muscle. SMA is caused by deletion of the telomeric survival
motor neuron 1 (SMN1) gene on chromosome 5q13 [18,19]. A cen-
tromeric (SMN2) copy of SMN1 exists as an inverted duplication [20].
The coding sequence of SMN2 differs from that of SMN1 by a single
nucleotide (840 CNT) which disrupts an exonic splicing enhancer and
results in the exclusion of exon 7 from the SMN2 transcript [21]. Thus,
whereas the SMN1 gene produces full length SMN protein (FL-SMN),
the SMN2 gene produces predominantly exon7-deleted SMN, which is
unstable and rapidly degraded, and a small amount of FL-SMN. The
latter is not able to fully compensate for the loss of SMN1 but SMN2
can modify disease severity in a copy number-dependent manner
[22]. How the depletion of FL-SMN protein culminates in the loss of
motor neurons is unclear but alterations in nuclear bodies have been
critically implicated in disease pathogenesis.
SMN functions as part of a large protein complexwhich includes, in
addition to SMN itself, 7 additional proteins, the Gemins [23]. The
function of the SMN complex is discussed in detail in a recent review
[23]. Brieﬂy, this complex is involved in the initial stages of
spliceosome assembly by binding Sm proteins in the cytoplasm and
transferring them as a heptameric ring on the Sm site of small nuclear
RNAs to produce U snRNPs, the functional unit of the spliceosome. The
spliceosome is responsible for the pre-messenger RNA splicing pro-
cess which, in turn, is essential for the successful execution of euka-
ryotic gene expression and cell survival. In neurons, SMN protein is
localized throughout the cytoplasm as well as in nuclei, where it is
restricted to gems and to CBs. Gems are discrete, spherical nuclear
bodies that have a size and shape similar to CBs [24]. Gems have been
implicated in the pathogenesis of SMA. Thus, consonant with the
depletion of SMN, gems are lost from the nuclei of motor neurons
of SMA patients and the extent of gem loss correlates with disease
severity [19,25]. Dysfunctional targeting of SMN to nuclear foci is a
cardinal feature of SMA [26]. Most SMA causing mutations result in a
truncated form of the protein that lacks sequences critical for self-Table 2
The neuronal intranuclear inclusion neurodegenerative diseases
Disease Gene/protein Neurons Glia HE
Unstable repeat diseases
Protein-mediated (PolyQ)
HD HD (IT15)/huntingtin NNC20, 21 No
DRPLA DRPLA/atrophin 1 NNC25, 30 N25, 37 Yes25
SBMA AR/androgen receptor N32 No
SCA1 SCA1/ataxin 1 N23, 24 C29
SCA2 SCA2/ataxin 2 CNN34, 40 C40
SCA3 SCA3/ataxin 3 NNC22, 36, 38 C38
SCA6 CACNA1A/CACNA1A CNN35 No
NNNC3
SCA7 SCA7/ataxin 7 1 No
SCA17 SCA17/TBP N39 No Yes27
Protein-mediated (PolyA)
OPMD PABPNI/PABPNI N No
RNA-mediated
DM1 DMPK/DMPK N No
DM2 ZNF9/ZNF9 N/I N/I
FXTAS FMR1/FMRP N N Yes
Others
NIID FTD Unknown N N Yes
FTLD-U-NI PGRN/PGRN CNN N
IBMPFD VCP/VCP NNC N
NIFID Unknown CNN No Yes
MSA Unknown CNN CNN
Neuroferritinopathy FTL/FTL NNC NNC Yes
References have been supplied for items not discussed in the text. ⁎ denotes evidence from
not in text: XII, hypoglossal nucleus; ac, anterior commissure; amyg, amygdala; bg, basal gan
type, a1A subunit; cb, cerebellum; cb ctx, cerebellar cortex; cpc's, choroid plexus epithelial ce
ec's, ependymal cells; gp, globus pallidus; hc, hippocampus; ic, internal capsule; imlcc, interm
locus coeruleus; N, nuclear; nbM, nucleus basalis of meynert; NI, not investigated; Pkj, Purki
subthalamic nucleus; str, striatum; thl, thalamus. Reprinted with permission from: Woulfe J
work in progress. Neuropathology and Applied Neurobiology 2007;33:2–42. Wiley-Blackweoligomerization [27] and proper translocation to the nucleus, both
necessary for gem formation.
Nuclear bodies do not function in isolation but showdynamic spatial
interactions with one another reﬂecting a highly co-ordinated intra-
nuclear functional network. Accordingly, pathological alterations affect-
ing one type of nuclear body should have consequences for the nuclear
bodies with which they interact. Experimental studies suggest that this
is the case for Gems and CBs in SMA [26]. The tight association between
these two nuclear bodies has raised questions regarding whether they
are truly separate entities [28]. SMNand p80 coilin, the principal protein
constituentof CBs, have very similar intranuclear localizationpatterns in
neurons, including localization to perinucleolar caps [24]. However, in
some cells and under some conditions, p80 coilin and SMN label distinct
structures [28]. Gems, per se, reportedly do not contain snRNP whereas
CBs do [24]. Regardless of whether they are distinct structures, it is clear
that there are molecular interactions between the two. The recruitment
of SMN to nuclear bodies is dependent on p80 coilin, indicating that
coilin provides a molecular bridge between CBs and gems [26]. The
functional inter-relationship between Gems and CBs is reﬂected by
alterations in the latter under conditions of SMNdepletion. Thus, Girard
and co-workers [29] described loss of canonical CBs in SMN-depleted
Hela cells with the formation of multiple small coilin foci and
localization of coilin to the nucleolus. These coilin foci did not contain
snRNPs. Frugier et al. [30] also provided evidence for defects in CB
assembly in motor neurons of a mouse model of SMA in which mutant
SMN lacking the carboxy-terminus was targeted to neurons. Immunos-
taining for p80 coilin revealed loss of typical CBs and the formation of
large intranuclear aggregates.
The involvement of CBs and coilin in the pathogenesis of SMA has
important implications for our understanding of the potential
involvement of the nucleus not only of this disease, but other neuro-
degenerative diseases as well. As speculated by Matera and Frey [28],
it could be interpreted to suggest that aberrations in other aspects of
the snRNP pathway (for example p80 coilin mutations), by analogy
with SMA, could also have neurodegenerative phenotypes.Ubiq PML 1C2 NI localization in nervous system
Yes Yes⁎⁎ Yes ctx, str
Yes Yes Yes ctx, gp, str, cb ctx, stn, rn, dn
Yes ? Yes spinal and bulbar motor neurons
Yes Yes⁎ Yes pons, ion
Yes Yes Yes pons, sn, ion, thl, gp, lc, ctx
Yes Yes Yes pons, dn, sn, thl, nbM, lgn, ctx
No33 ? Yes Pkj
Yes Yes Yes ctx, lgn, pons, ion, sn, Pkj, pons, raphe, thl, nbM, cb
Yes Yes Yes ctx, ctx
Yes Yes⁎ No cb ctx
No ? No hc, dg, thl, sn, Pkj
No ? No NI
Yes Yes⁎⁎ No hc, ctx, bg, sn, thl, dn, ion, XII, ec's, cpc's
Yes Yes Yes/No ctx, hc, bg, thl, cb, bs, sc, drg, pn
Yes Yes No ctx, dg, str
Yes Yes⁎⁎ No ctx, hc, str, gp
Yes ? Yes/No ctx, hc, dg, amyg, str, gp, thl, rn, sn, pons, ion,Pkj
Yes ? No widespread; bg, cb, pons, ion, imlcc
Yes ? No str, gp, ctx, cb ctx, pn, ic, ac, cpc's
experimental studies only. ⁎⁎ denotes evidence from author's laboratory. Abbreviations
glia; bs, brainstem; C, cytoplasmic; CACNA1A, calcium channel, voltage-dependent, P/Q
lls; ctx, cerebral cortex; dg, dentate gyrus; dn, dentate nucleus; drg, dorsal root ganglia;
ediolateral cell column; ion, inferior olivary nucleus; IT15, interesting transcript 15; lc,
nje cells; pn, peripheral nerve; rn, red nucleus; sc, spinal cord; sn, substantia nigra; stn,
M, Abnormalities of the nucleus and nuclear inclusions in neurodegenerative disease: a
ll publishing.
Fig. 1. PML staining of NIs. Double immunostaining for ubiquitin (red) and PML (green)
of NIs in a cortical neuron in HD (a), an astrocyte in the pontine white matter in fragile
X-associated tremor ataxia syndrome (b). Note multiple normal PML bodies in (a). Also
note the linear PML body in the astrocyte in (b). c, d) A small ubiquitinated NI in a
cortical neuron in neuronal intranuclear inclusion disease is PML-immunoreactive
(c) whereas a large NI in the same case is negative for PML (d). This size-dependency of
PML positivity inspired the model depicted in (e) whereby NIs seed in PML bodies. As
more protein accumulates, the NI outgrows the PML body, culminating in the formation
of a large NI lacking PML immunoreactivity. Bars=5 μm. Tissue from HD case in a
provided by Dr. Yves Robitaille. Tissue from FXTAS case in b provided by Dr. Marc
DelBigio. Illustration in (e) by Dr. Douglas A. Gray. Reprinted with permission from:
Woulfe JM, Abnormalities of the nucleus and nuclear inclusions in neurodegenerative
disease: a work in progress. Neuropathology and Applied Neurobiology 2007;33:2–42.
Wiley-Blackwell publishing.
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A number of neurodegenerative diseases are characterized patho-
logically by the presence of microscopically-visible, proteinaceous
intranuclear inclusion bodies (NIs) within neurons and, less com-
monly, glial cells. The mere presence of these imposing structures
within the nucleus has led to investigations of how they might
interact with, or disrupt the function of, nuclear compartments. The
“nuclear inclusion” diseases comprise a large family including the
polyglutamine (polyQ) repeat diseases, the polyalanine (polyA)
repeat diseases, the RNA-mediated diseases, subtypes of frontotem-
poral dementia, neuronal intranuclear inclusion disease, multiple
system atrophy, and neuroferritinopathy (see Table 2). A complete
discussion of the clinical features, pathological features, and pa-
thogenesis of these disorders is the subject of a previous review [4].
The NIs consist of aggregation-prone mutant proteins (in the case of
hereditary diseases) or otherwise post-translationally altered/mis-
folded proteins (in the case of sporadic diseases), or expanded RNA
and RNA-binding proteins (in the case of the RNA-mediated
diseases). In the case of the polyQ repeat diseases, an unstable CAG
(the codon for glutamine) trinucleotide repeat expansionmutation in
the affected gene leads to the production of a mutant protein with a
long expansion of glutamine (Q) residues. This polyQ tract confers on
the protein a toxic gain-of-function and results in the appearance of
NIs consisting of ubiquitinated insoluble mutant polyQ protein. The
role these inclusions play in causing neuronal degeneration is uncer-
tain. The prevailing theory posits that the formation of visible
ﬁlamentous intranuclear inclusion bodies is a protective mechanism
to sequester more soluble, toxic oligomeric or protoﬁbrillar forms of
the pathogenic protein in an intranuclear “safehouse” [31]. On
the other hand, the ability of NI's to bind functionally important
nuclear proteins, including transcription factors, components of the
ubiquitin-proteasome system and, in the case of the RNA-mediated
diseases, RNA splicing factors, has engendered the concept that NI's
effectively deplete the nucleus of these proteins with consequent
transcriptional, degradative, and splicing dysregulation. Of these,
transcriptional dysregulation has received the most attention as a
potential pathogenic mediator [32,33].
The inﬂuence of NI's on nuclear body organization and func-
tion has been most extensively studied with respect to PML
bodies. These spherical, 0.1 to 2 μm diameter bodies have been
implicated in transcriptional regulation, growth suppression, apop-
totic cell death, DNA repair, intranuclear protein storage and
proteolysis, and in the controversial phenomenon of intranuclear
protein translation [8]. PML, the signature protein of PML bodies
has een shown to localize to NIs in a number of polyQ diseases [34–41]
where it typically forms a ring, or shell around a ubiquitin-positive
core. PML localization to NI's is not conﬁned to polyQ diseases.
We have observed PML staining of NIs in a variety of NI diseases
(Fig. 1a–c).
As described by others [40,42], the association of PML with NIs is
size-dependent whereby PML staining is conﬁned to small NIs with
larger ones being PML negative (Fig. 1c, d). This has been interpreted
to suggest a model for PML-associated NI formation (Fig. 1e) which
implicates “seeding” of mutant protein within pre-existing PML
bodies [40–42]. Further protein recruitment leads to enlargement
with eventual “obliteration” of the PML body. In this scenario, PML
bodies represent sites of NI formation. Fu and co-workers provided
evidence that large NIs form by fusion of smaller PML-associated NIs
[43]. They demonstrated amarked re-distribution of PML bodies along
the surface of NIs in the absence of changes in CBs or nuclear speckles.
The NI-induced disruption of PML bodies may have pathogenic con-
sequences. For example, the stress responses of PML bodies are
ablated by mutant ataxin 1 (the protein that accumulates in nuclear
inclusions in spinocerebellar ataxia type 1) and other nucleoprotein
inclusions [44]. This is associated with loss of typical PML bodies fromnuclei harbouring PML-immunoreactive NIs. Moreover, in the polyQ
disease dentatorubropallidoluysian atrophy, there is altered abun-
dance of RE repeats encoded protein, a protein normally localized to
PML bodies [11]. In keeping with the purported proteolytic function of
PML bodies, it is also conceivable that the size-dependent association
of PML and NIs reﬂects successful intranuclear proteolysis of NI
protein. PML is a ring ﬁnger proteinwith purported E3 ubiquitin ligase
activity [45] and it could be involved in the degradation of abnormal
Fig. 2. SUMO staining of NIs. NIs in cortical neurons in cases of neuronal intranuclear
inclusion disease (a), FTLD-U (b), and IBMPFD (c) double-immunostained for ubiquitin
(green) and SUMO-1 (red). Bars=5 μm. Tissue from neuronal intranuclear inclusion
disease and FTLD-U-NI cases in a, b provided by Dr. Ian Mackenzie. Tissue from IBMPFD
case in c provided by Dr. Mark Forman. Reprinted with permission from: Woulfe JM,
Abnormalities of the nucleus and nuclear inclusions in neurodegenerative disease: a
work in progress. Neuropathology and Applied Neurobiology 2007;33:2–42. Wiley-
Blackwell publishing.
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themselves described “empty large nuclear bodies” showing ring-
like PML staining surrounding a polyQ-negative core. They interpreted
these changes in staining properties as successful proteolysis of polyQ
protein in pre-existing NIs. There could be therapeutic implications in
elucidating whether: 1) PML nuclear bodies are involved in the
formation or degradation of NIs and 2) NIs are toxic or protective. A
variety of environmental or pharmacological manipulations cause
alterations in PML bodies [46]. These manipulations might someday
be exploited to enhance or, alternatively, mitigate NI formation.
Alterations in CBs in neurodegenerative disease have been less
extensively scrutinized. These subnuclear domains play a critical role
in the biogenesis of snRNPs, integral components of the pre-mRNA
splicing machinery, and splicing aberrations have been implicated in a
number of neurodegenerative diseases. CBs are not affected by the
presence of NIs composed of polyQ-expanded ataxin 1 [34], but are
closely associated with the NIs in the polyQ diseases dentatorubro-
pallidoluysian atrophy and spinocerebellar ataxia type 3 [38]. Sun and
co-workers [47] demonstrated that NIs composed of mutant ataxin-3,
but not ataxin-1 or huntingtin, were “tethered” to CBs in vitro
conﬁrming a differential effect of distinct polyQ proteins on CB
organization. Moreover, mutant ataxin-3 was able to disrupt the
splicing of an artiﬁcial reporter, providing evidence for the pathogenic
potential of the NI-CB interaction. The mechanism for this functional
effect remains uncertain since the association frequency of CBs with
U2 genes was not altered. This work calls into question the prevailing
theory that NIs in polyQ neurodegenerative diseases are all protective.
Of potential interest to neurodegenerative disease are the SUMOy-
lation bodies recently described by Navascues and co-workers in a
PC12 neuron-like cell line [48]. SUMOylation is a molecular regulatory
pathway involving the covalent attachment of the small ubiquitin-like
modiﬁer (SUMO) to lysine residues [49]. It is emerging as an important
mechanism of transcriptional control [50,51] and as a crucial player in
neurodegenerative pathophysiology [52]. SUMO-1 nuclear bodies
(SNBs) are 1 to 3 μm in diameter, are free of PML protein, splicing
factors, and transcription foci, and show spatial association with CBs.
Theyconcentrate the transcriptional regulators CBP, CREB and c-jun. By
compartmentalizing them, SNBs may participate in the control of the
nucleoplasmic concentration of transcriptional regulators involved in
neuroprotection and survival [48]. SUMO modiﬁcation has been im-
plicated in human neurodegenerative disorders [53]. NIs in neuronal
intranuclear inclusion disease contain SUMO-1 and the SUMOylation
substrates PML, histone deacetylase 4, and RanGap1, suggesting that
recruitment of SUMO-1 modiﬁed proteins into NIs may contribute to
disease pathogenesis [42,54]. We have demonstrated SUMO-1 immu-
noreactivity of NIs in a variety of NI neurodegenerative diseases (Fig. 2).
Aberrant SUMOylation has also been implicated in neurodegenerative
diseases without obvious nuclear morphological changes (for an
excellent review see [52]).
The unique SUMO-containing PML nuclear bodies described in
neurons of the supraoptic nucleus [55] and the substantia nigra
(Fig. 3) [56] may represent an SNB equivalent in the human brain. It
will be interesting to determine how these structures are altered in
neurodegenerative disease.
5. Nuclear bodies in common neurodegenerative diseases
Until recently, alterations in nuclear structure and function have
been relatively neglected in more common neurodegenerative dis-
orders like Alzheimer's disease (AD), Parkinson's disease (PD),
frontotemporal dementia (FTD), and amyotrophic lateral sclerosis
(ALS) perhaps because these diseases lack obvious nuclear morpho-
logical changes. Instead, cytoplasmic or extracellular protein aggre-
gates represent the histopathological hallmarks of these diseases.
Indeed, in rare families, causative mutations in genes encoding the
aggregated proteins attest to the importance of these proteins indisease pathogenesis. However, the vastmajority of cases are sporadic,
with no evidence of mutations in the genes for these aggregating
proteins. The pathophysiological mechanisms leading to protein ag-
gregation in sporadic forms of these neurodegenerative diseases are
unknown. However, evidence is accumulating that risk factors for
these diseases may lie within the conﬁnes of the nuclear membrane;
involving alterations at the level of gene expression and splicing, or
mediated by “polymorphisms” in regulatory regions of the genes
encoding disease-relevant proteins [57,58]. Moreover, the abnormal
localization of nuclear transcription factors may represent a common
feature of a variety of neurodegenerative disorders [5]. To what extent
is this nuclear involvement reﬂected by nuclear morphological
changes and, more speciﬁcally, alterations in nuclear bodies? Ultra-
structural investigations of AD have revealed irregularities in the
nuclear envelope including fragmentation, prominent nuclear pore
aggregation, and a close association with paired helical ﬁlaments
[59,60]. Some studies have reported the presence of NIs in AD [61].
Toper and co-workers [62] reported intranuclear rodlets, spherical
inclusion bodies, and “vermicellar-like” inclusions. However, how
these nuclear functional alterations are reﬂected in, or alternatively,
are consequent upon, changes in nuclear bodies, are in their infancy.
5.1. Alzheimer's disease
Alzheimer's disease (AD) is a common, dementing, relentlessly
progressive neurodegenerative disorder of unknown etiology [63].
The histopathological hallmarks of AD are extracellular deposits of
β-amyloid protein in the cerebral cortex and intracellular deposits of
hyperphosphorylated tau protein in the form of neuroﬁbrillary tangles.
There is strong evidence for a role for β-amyloid and tau protein in
AD pathogenesis [64]. β-amyloid is generated by sequential proteolytic
cleavage from a larger, type I transmembrane protein called amyloid
precursor protein (APP), encoded on chromosome 21. This processing is
accomplished by the actions ofβ-secretase andγ-secretase (reviewed in
Fig. 3. SUMO-immunoreactive PML body and Marinesco body (arrow) within the nucleus of a human substantia nigra neuron double-immunostained for PML (green) and SUMO
(red). Counterstained with DAPI (blue). The nuclear membrane is indicated with a solid line and the nucleolus with a dotted line. Note the juxtaposition to nucleoli (dotted line).
Bar=5 μm. Reprinted with permission from: Woulfe JM, Prichett-Pejic W, Rippstein P, Munoz DG. Promyelocytic leukemia immunoreactive neuronal intranuclear rodlets in human
brain. Neuropathology and Applied Neurobiology 2007;33:56–66. Wiley-Blackwell publishing.
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changes in gene expression [66]. Thus, in addition to generating the
pathogenic Aβ, these cleavage events generate a large amino terminal
fragmentof APP aswell as a carboxy-terminal fragment, Cγ (reviewed in
[64,65]). APP may signal to the nucleus via Cγ, which is transported to
the nucleus in a complex with the adaptor protein Fe65 where it may
regulate transcription throughas yetundeterminedmechanisms [67]. In
addition to this role in transcriptional regulation, Cγ may have other
nuclear roles. Muresan and Muresan demonstrated that a phosphory-
lated form of Cγ localizes to nuclear splicing speckles (but is excluded
from CBs and Gems) [68]. They suggested that splicing speckle Cγmay
have a role in pre-mRNA splicing. In this context, it would be interesting
to know whether, and how, nuclear splicing speckles are altered in AD.
Indeed, there is evidence for transcriptional and post-transcriptional
dysregulation in AD [69]. Total cellular RNA and polyA RNA are sub-
stantially reduced in theAD cortex [70]. At thepost-transcriptional level,
there are alterations in RNA-binding proteins [71]. This transcriptional
dysregulation may involve CBP [72,73]. Reduced levels of CBP and the
subsequent reduction in expression of CREB/CBP target genes have been
found in familial AD [74]. A model of transcriptional dysregulation in
familial AD based on impaired cleavage of transcriptionally-active, non-
APP substrates, such as Notch-1 has been proposed [69,75].
Tau protein, the constituent protein of cytoplasmic neuroﬁbrillary
tangles, has also been implicated in AD pathogenesis [76]. Tau is a
microtubule associated protein which promotes microtubule stability
[77]. In AD, tau becomes hyperphosphorylated and forms neuroﬁ-
brillary tangles. How hyperphosphorylated tau protein and/or NFTs
damage neurons in AD is uncertain, but intranuclear mechanismsmay
be involved. The demonstration of intranuclear paired helical ﬁla-
ments (the ultrastructural counterpart of neuroﬁbrillary tangles) in
AD [59] is compatible with the presence of tau in the nucleus of
normal neurons as well as non-neuronal cells [78–81]. Normal tau has
DNA binding capacity and may protect DNA from denaturation [82].
Nuclear tau localizes to the internal periphery of nucleoli, partially co-
localizing with nucleolin and directly binding with AT-rich α-satellite
DNA sequences organized as constituitive heterochromatin [83]. Be-
cause perinucleolar heterochromatin and the associated proteins have
an important role in the regulation of nucleolar structure [84], the
latter authors proposed that nucleolar tau participates in the orga-
nization of the nucleolus and/or the heterochromatization pattern of a
subset of RNA genes. In the setting of AD, hyperphosphorylated,
aggregation-prone nuclear tau loses its capacity to interact with DNA
[85] and could thereby disrupt nucleolar organization, or alternatively,
the association of certain genes with the nucleolus. In this context, it is
interesting that there is a lower frequency of satellite association in
relation to chromosome 21 in AD, a provocative ﬁnding in light of thelocalization of the APP gene on this chromosome. Alterations in rRNA
levels have been reported in AD [86,87]. However, studies of post-
mortem AD brain tissue reveal no effect of neuroﬁbrillary tangle
formation, per se, on nucleolar size [88]. There are conﬂicting results
regarding the size of nucleolar organizer regions in AD relative to age-
matched controls with some studies showing a decrease [89] and
others showing a (compensatory?) increase [90].
In AD, the formation of NFTs involves tau hyperphosphorylation
[91]. In other tauopathies, the formation of NFTs results from aberrant
mRNA splicing of exon 10 [92]. Glycogen synthase kinase-3 (GSK-3) is a
key enzyme regulating tau metabolism and has been implicated in
bothmechanisms [93]. GSK-3 accumulates in the cytoplasmof neurons
developing NFTs in AD and other tauopathies [94]. Interestingly, in-
hibitingGSK-3 in cultured neurons resulted in aberrant splicingof exon
10 and an enrichment of SC35 in nuclear splicing speckles where it co-
localized with GSK-3 [95]. Moreover, nuclear GSK-3 phosphorylated
SC35 protein. In this context, it is tempting to speculate that abnor-
malities in GSK-3 function or localization to nuclear splicing speckles
might have a role in the pathogenesis of tauopathies not linked to
mutations in the tau gene, or even to AD.
We have provided evidence for involvement of another, neuron
speciﬁc, nuclear body in the pathogenesis of AD. Neuronal intranuclear
rodlets (INRs) are rod-shaped intranuclear bodies present in the normal
human brain where they show a widespread but anatomically hete-
rogeneouspatternof distribution (Fig. 4a) [96]. Theycanbedemonstrated
in a variety of mammalian species as well as in neurons in vitro. The
functional signiﬁcanceof these structures is unknownbut their formation
has been linked to changes in neuronal electrical or transcriptional/
translational activity [97,98]. In our studies of the functional signiﬁcance
of INRs, we have demonstrated non-random spatial interactions with
other nuclear bodies including nucleoli and PML bodies [56,99]. This is
consistent with previous electron microscopic studies demonstrating
spatial interactions between INRs and CBs [100]. We have demonstrated
that neuronal INRs are signiﬁcantly and markedly depleted in the
temporal cortexofADpatients relative to controls and thosewith another
common age-related neurodegenerative dementia, dementia with Lewy
bodies [101]. We are currently investigating the functional and
pathological signiﬁcance of this phenomenon but, given our evidence
for an interaction of INRs with other nuclear bodies, it is consistent with
the data presented above for nuclear involvement in AD pathogenesis.
5.2. Parkinson's disease
Parkinson's disease is the most common neurodegenerative move-
ment disorder and is characterized pathologically by a relatively se-
lective loss of dopaminergic neurons in the substantia nigra. The vast
Fig. 4. Fluorescence microscopy images of human SN neurons double-immunostained for PML (green) and class III beta tubulin (C3T; red). Three types of immunostained structures
are demonstrated including C3T+/PML-typical INR (a), C3T-/PML+ nuclear bodies (b) and C3T+/PML+ INR (c). The nuclear membrane is indicated by a solid line, and the nucleolus by a
dotted line. Note the juxtanucleolar location in c. Bar=5 μm. Reprinted with permission from: Woulfe JM, Prichett-Pejic W, Rippstein P, Munoz DG. Promyelocytic leukemia
immunoreactive neuronal intranuclear rodlets in human brain. Neuropathology and Applied Neurobiology 2007;33:56–66. Wiley-Blackwell publishing.
2201J. Woulfe / Biochimica et Biophysica Acta 1783 (2008) 2195–2206majority of cases are sporadic. Rare familial cases with autosomal
dominant or autosomal recessive inheritance have provided clues
regarding pathogenesis of the sporadic form of the disease. A protein
calledα-synuclein has emerged as a keyplayer in disease pathogenesis
[102]. Missensemutations inα-synuclein cause PD in rare kindreds. In
others, duplications, or triplications, of theα-synuclein gene cause PD,
indicating a role forα-synuclein dosage in causing the disease. Finally,
in both familial as well as sporadic forms of the disease,α-synuclein is
the principle protein constituent of Lewy bodies, the roughly spherical
intracytoplasmic inclusion bodies that are the histopathological hall-
mark of PD. In normal neurons, α-synuclein localizes to presynaptic
axon terminals and to the nucleus [103]. The majority of studies of this
important protein have focused on it's role in the axon terminal.
However, it's nuclear localization has been reported in a variety of
species as well as in vitro [104,105]. Moreover, α-synuclein forms
neuronal and glial intranuclear inclusions in patients with a neurode-
generative disorder known asmultiple system atrophy [106] as well as
inmice expressing humanα-synuclein [107]. Synuclein translocates to
the nucleus of mice injected with the PD-inducing herbicide paraquat
and, once in the nucleus, can associate with histones, suggesting that
the abnormal formation of histone-α-synuclein complexes may have
relevance for PD pathogenesis [104]. Indeed, α-synuclein mutations
that cause familial PD exhibit increased nuclear targeting in vitro [108].
The latter authors provided strong evidence that α-synuclein me-
diates neurotoxicity in the nucleus by demonstrating that targeting of
α-synuclein to the nucleus promoted toxicity whereas cytoplasmic
sequestration was protective. Moreover, α-synuclein bound directly
to histones, reduced the level of acetylated histone H3, and inhi-
bited acetylation in histone acetyltransferase assays. Remarkably, the
toxicity of α-synuclein could be rescued by administration of HDAC
inhibitors, revealing potential therapeutic relevance for aberrant
intranuclear interactions of α-synuclein in PD.
Despite this impressive evidence for a pathogenic intranuclear role
for α-synuclein, it's intranuclear distribution is described as diffuse
[108] or “uneven with a reduced presence in nucleoli” [109] with no
reference to any particular nuclear body. Moreover, whether nuclear
bodies are re-organized or otherwise altered as a consequence of
intranuclear α-synuclein dysfunction in PD remains to be investi-
gated. Gertz and co-workers [110] found no signiﬁcant difference in
nucleolar size when comparing neurons with Lewy bodies and
without Lewy bodies in PD brain, suggesting no inﬂuence of cyto-
plasmic α-synuclein aggregation on RNA synthetic activity. However,
there was a signiﬁcant negative correlation between nucleolar size
and duration of disease.Of potential relevance to PD and the substantia nigra are Marinesco
bodies (MBs) and INRs. MBs are predominantly spherical eosinophilic
intranuclear bodies found in pigmented neurons of the substantia nigra
and locus coeruleus of the non-diseased human brain. Whether they
represent nuclear bodies or “quasi-pathological” nuclear inclusions is a
matter of debate. Like disease-associated NIs, MBs are immunoreactive
for ubiquitin [111], ataxin-3 [112], PML [113], and SUMO-1 (Fig. 3). In-
terestingly, MBs are also SUMOylated and contain histone deacetylase 4
[114]. The frequency of MBs increases with age [115,116]. It has been
postulated that MB formation is a response to cellular stress or to
impaired handling of intranuclear protein [115–117]. The age-related
increase in MBs has been implicated in the selective vulnerability of
these neurons to degeneration in aging and in PD [118]. MBs are sig-
niﬁcantly increased in nigral neurons of patients with dementia with
Lewy bodies and in Lewy body-bearing neurons [119]. In one study, MB
frequency correlated signiﬁcantly, and inversely,withmarkers of striatal
dopamine in non-diseased elderly subjects [119]. We have demon-
strated that INRs in dopaminergic neurons of the human substantia
nigra show intimate, non-random spatial interations with MBs and
postulated that MBs may arise from INRs or vice versa [99].
Injection of mice with the selective dopaminergic neurotoxin MPTP,
results in the degeneration of neurons in the substantia nigra and
represents a widely used animal model of PD [120]. We have de-
monstrated a signiﬁcant upregulation in the number of INRs in do-
paminergic neurons in MPTP-treated mice, suggesting possible
involvement of this structure in PD pathogenesis [121]. These ﬁndings
are intriguing because in dopaminergic neurons of the human sub-
stantia nigra, INRs showan interactionwith PMLand features not seen in
other areas of the central nervous system (with the possible exception of
the PML nuclear bodies in the supraoptic nucleus [55]). Here, in addition
to typical rod-shaped INRs (Fig. 4a) and spherical PML bodies (Fig. 4b),
there are roughly spherical to elongated, PML-immunoreactive INRs
consistently associated with the nucleolus (Fig. 4c), and with MBs [99].
These show a central zone of tubulin or glucocorticoid receptor staining
surrounded by a PML-immunoreactive ring (Fig. 4c), similar to the
pattern described for disease-associated NIs [56]. A proportion also
show immunostaining for ubiquitin, SUMO-1 (Fig. 3) and 20S protea-
some [56]. Staining for the latter is interesting in light of a study
demonstrating nuclear localization of the 20S proteasome in PD, but not
control substantia nigra [122]. Curiously, a small proportion of INRs are
immunoreactive for acetylated histone H4, indicating the presence of
trancriptionally-active chromatin as well as for the eukaryotic transla-
tion initiation factor eIF4e. Finally, they show immunoreactivity for CBP.
Whether these special features of INRs in dopaminergic neurons have
Fig. 5. Dentate gyrus of the hippocampus from a patient with FTLD-U immunostained
for TDP-43. Neurons with cytoplasmic (arrowhead) or intranuclear (arrows) inclusions
show a loss of the normal diffuse nuclear pattern of TDP-43 (shown at higher power for
intranuclear inclusions in insets. Bars=5 μM. Photograph courtesy of Dr. Juan Bilbao.
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5.3. Frontotemporal dementia
Frontotemporal dementia (FTD) is a clinically, genetically, and
pathologically heterogeneous group of diseases characterized by
changes in personality and social behaviour with relative preserva-
tion of memory and perception [123,124]. A genetic basis for FTD is
supported by the presence of a family history in approximately half of
all cases [125]. Pathologically, FTD is characterized by varying degrees
of frontal and temporal lobar degeneration. Two groups can be
discerned on the basis of histopathology and immunohistochemis-
try: those featuring tau-immunoreactive cytoplasmic neuroﬁbrillary
inclusions (the tauopathies) and those lacking tau-positive inclusions
(the non-tauopathies). The non-tauopathies account for 60% to 72% of
all patients with FTD [123,126]. They include dementia lacking
distinctive histopathology, frontotemporal lobar degeneration with
ubiquitin-only inclusions (FTLD-U), frontotemporal dementia with
motor neuron disease (FTD-MND), neuronal intermediate ﬁlament
inclusion body disease (NIFID), and inclusion body myopathy/Paget's
disease of bone/frontotemporal dementia (IBMPFD) [124,126–131].
FTLD-U is themost common type of FTD, comprising up to 62% of all
patients and almost all patients with non-tauopathy FTD. Histopatho-
logically, FTLD-U is characterized by the presence of ubiquitin-
immunoreactive, tau- and synuclein-negative dystrophic neurites and
neuronal cytoplasmic inclusions in neurons of the hippocampus and
cerebral cortex [124]. The inclusions are similar to those described in
motor neurons of amyotrophic lateral sclerosis (ALS) and, indeed pure
motor neuron disease and FTLD-U represent two extremes of a
clinicopathological spectrum [132]. Thus, understanding the nuclear
pathology of FTLD-U has important implications with respect to elu-
cidating the pathophysiology of ALS (see below).
We demonstrated that a subset of patients with FTLD-U harboured,
in addition to cytoplasmic inclusions, ubiquitinated, round-, rod-, or
lens-shaped inclusions within the nucleus [133]. NIs in FTLD-U also
show immunostaining for SUMO-1 [134] and variable immunoreactivity
to heat shock proteins 40 and 70 [135], p62 [135], valosin-containing
protein (VCP) and PML [132,134,135]. Notably, NIs are reportedly ne-
gative for CREB or CBP [134]. In our original study, all patients with NIs
had a family history suggestive of autosomal dominant inheritance [133]
and the linkbetweenNIs in FTD and familial diseasewas later conﬁrmed
[136]. Linkage analyses of FTLD-U families with NIs ultimately led to
elucidation of the genetic basis of FTLD-U with NIs; mutations in the
progranulin (PGRN) gene [137,138] located amere 1.7Mb centromeric of
the highly viliﬁed TAU gene. Progranulin is a 593 amino acid growth
factor expressed in several tissues which has roles in development,
tissue repair, and inﬂammation [139]. Haploinsufﬁciency for this growth
factor in the CNS has been postulated as the pathogenetic substrate for
FTLD-Uwith NIs. Other genes for FTLD-U have been identiﬁed including
the chromatin-modifyingprotein 2B (CHMP2B) on chromosome3 [140],
and within a 9.8 Mb region at chromosome 9p13.2-21.3 [141,142].
Inclusion body myositis/Paget's disease of bone/frontotemporal
dementia (IBMPFD) is a rare, autosomal dominant disorder caused by
[129] mutations in the gene encoding VCP [143], a member of the AAA-
ATPase gene superfamily (ATPase Associated with diverse cellular Activ-
ities) [144,145]. The histopathological basis of FTD in IBMPFD is the
presence of ubiquitinated intranuclear inclusion bodies in cortical neu-
rons as well as dystrophic neurites and only rare cytoplasmic inclusions.
In contradistinction to the nuclear inclusion diseases discussed
above, the NIs in FTLD-U and IBMPFD do not appear to be composed
primarily of the protein which is mutated. Instead, the principle
constituent of the NIs, as well as the cytoplasmic inclusions, in these
disorders is transactive response DNA binding protein 43 (TDP-43;
Fig. 5) [146,147]. As predicted, the cytoplasmic inclusions in sporadic
ALS are also immunoreactive for TDP-43 [146]. The TDP-43 within NIsand cytoplasmic inclusions in these “TDP-43 proteinopathies” displays
a characteristic biochemical signature whereby it consists of hyper-
phosphorylated and ubiquitinated carboxy-terminal fragments [146].
How PGRN or VCP mutations culminate in aberrant TDP-43 cleavage,
phosphorylation, ubiquitination, and aggregation is uncertain. Inter-
estingly, it has been demonstrated that progranulin mediates the
caspase-dependent cleavage of TDP-43, providing a possible mechan-
istic link [148].
In normal cells, TDP-43 displays awidespread nuclear distribution.
In FTLD-U, IBMPFD, and ALS, NIs and cytoplasmic inclusions exhibit
intense TDP-43 staining, at the expense of this pan-nuclear distribu-
tion (Fig. 5) [146]. This has been interpreted to suggest that the
formation of TDP-43 inclusions sequesters normal TDP-43 from its
normal intranuclear location(s), thereby abrogating its function and
culminating in neurodegeneration. What function normally mediated
by nuclear TDP-43 might be disrupted by this mechanism in FTLD-U?
TDP-43 is a highly conserved DNA- and RNA-binding, nuclear protein
that functions as a transcriptional repressor and activator of exon
skipping [149]. It achieves this through interaction with heteroge-
neous nuclear ribonucleoproteins, particularly hnRNP A1, A2/B1, A3,
and C1/C2 [150]. TDP-43 also interacts with SMN ([151] see below).
However, Neumann and colleagues demonstrated no biochemical
changes and no alterations in the subcellular pattern of distribution of
hnRNPs A1, A2/B1, C1/C2 or SMN in affected brain regions in patients
with FTLD-U [152]. In addition, pathological inclusions in FTLD-U did
not immunostain for the tested hnRNPs or SMN.
There is evidence that TDP-43 functions as a scaffold for nuclear
bodies through its interaction with SMN. Wang and co-workers [151]
demonstrated that TDP-43 is localized to multiple discrete subnuclear
structures and claimed that these represented a new category of
nuclear body, the TDP body (TB). TBs co-localized or overlapped
signiﬁcantly with multiple types of other nuclear bodies including
CBs, PML bodies, splicing speckles, and gems. They associated with the
latter through an interaction with SMN. Interestingly, TBs often
associated with multiple splicing speckles and gems. In addition, a
single TB was often identiﬁed in association with more than one type
of nuclear body including TB-Gem-CB, TB-Gem-POD, TB-speckle-CB,
and TB-speckle-PML body combinations. On the basis of these
observations, the authors proposed that TBs represent a bridge
serving to link nuclear bodies of the same, or different types. For
example, by bridging CBs and splicing speckles, they may provide the
spatial proximity necessary for coupling snRNP supply with RNA
splicing. Abrogation of this nuclear scaffold function of TDP-43 would
be predicted to have a profound affect on nuclear body organization
with attendant nuclear dysfunction.
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ALS is a progressive neurodegenerative disorder that involves
degeneration of themotor system at all levels [153]. Only 5–10% of ALS
patients have a positive family history and these usually show an
autosomal dominant pattern of inheritance. The remaining 90% of
cases seem to occur sporadically. As discussed above, there is con-
siderable overlap between both familial and sporadic FTLD-U and ALS
whereby these two disorders represent two extremes of a clinico-
pathological spectrum [128,132]. Indeed, immunoreactivity of the
characteristic cytoplasmic inclusion bodies in ALS for TDP-43 com-
bined with the fact that TDP-43 in ALS displays the pathogenic
biochemical signature seen in FTLD-U, suggests that sporadic ALS, like
FTLD-U, is a TDP-43 proteinopathy. Indeed a proportion of ALS cases
may be caused by mutations in the gene encoding TDP-43 [154]. Thus,
the discussion above regarding abnormal TDP-43 function in the
nucleus is also pertinent to ALS. On the other hand, evidence from 3-D
deconvolution microscopy indicates that TDP-43 might not be the
major ubiquitinated target in inclusions in sporadic ALS and that the
primary pathogenic protein remains to be identiﬁed [155].
Regarding studies of nuclear structure and nuclear bodies per se, in
ALS, much remains to be done. NIs distinct in morphology and
distribution from those in FTLD-U have been described in cortical and
hippocampal pyramidal neurons in otherwise typical cases of ALS
[156,157].These round, hyaline structures were immunoreactive for
ubiquitin, PML, proteasome, and non-expanded ataxin-3 [157]. In one
study, astrocytic PML bodies were implicated in ALS pathophysiology
[158]. Excitatory amino acid transporter 2 (EAAT2) is an astrocytic
glutamate transporter which under normal conditions is involved in
clearing the extracellular space of glutamate and mitigating excitotoxi-
city. Astrocytic EAAT2 activity is deﬁcient in ALS, possibly as a result of
aberrant caspase-mediated cleavage, implicating excitotoxicity in the
mechanisms underlying motor neuron degeneration. Gibb and co-
workers [158] demonstrated that a caspase-cleaved carboxy-terminal
fragment of EAAT2 is SUMOylated and transported to the nucleuswhere
it localized to PML bodies. In light of the involvement of PML bodies in
transcriptional regulation, they proposed that the recruitment of
SUMOylated EAAT2 carboxy-terminal fragment to PML bodies might
result in altered transcriptionwith, for example, increased generation of
toxic proteins. In this context, a possible role for PML bodies or other
nuclear bodies in ALS warrants further investigation.
6. Conclusions
Ongoing studies of the cell nucleus are revealing a remarkable
complexity of structure and function. Underlying this are not only the
dynamic interactions among nuclear bodies, emphasized in this review,
but also the structural and gate-keeping function of the nuclear
membrane, nuclear pores and their associated cytoskeletal complex as
well as the non-random localization of the chromosomes themselves to
“chromosome territories” [159]. The visually imposing protein aggre-
gates which represent the morphological hallmarks of neurodegenera-
tive disease have perhaps diverted attention away from the nuclear
compartment. However, as elucidated above, there is growing recogni-
tion that nuclear dysfunction may have an important role in these
diseases. Studies of nuclear body alterations in neurodegenerative
disease are in their infancy.However, based onwhat is known, it appears
that this may take many forms; the absence of gems in SMA, the
disruption of PML bodies and other nuclear bodies in the nuclear
inclusion diseases, the potential disruption of TDP-43-mediated linking
of nuclear bodies in FTD. For the more common sporadic neurodegen-
erative disorders, the story remains to be written. However, it is clear
that in addition to elucidating novel mechanisms of disease, studying
the nucleus in these neurodegenerative disorders could lead to the
development of potentially exciting disease-modifying therapies, such
as those targeting transcriptional regulation.Acknowledgements
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